Isatuximab: First Approval

@article{Dhillon2020IsatuximabFA,
  title={Isatuximab: First Approval},
  author={Sohita Dhillon},
  journal={Drugs},
  year={2020},
  volume={80},
  pages={905-912}
}
Isatuximab (isatuximab-irfc; Sarclisa ® ) is an IgG1 monoclonal antibody that binds to the glycoprotein CD38 expressed on the surface of haematopoietic and tumour cells. It is being developed by Sanofi, under a license from Immunogen, for the treatment of haematological malignancies. In March 2020, intravenous isatuximab (in combination with pomalidomide and dexamethasone) was approved in the USA for the treatment of adult patients with multiple myeloma who have received ≥ 2 prior therapies… Expand
Isatuximab, a novel anti-CD38 monoclonal antibody in the treatment of multiple myeloma: efficacy and safety
TLDR
The article discusses the place of CD38 antibodies in the treatment of multiple myeloma and special emphasis is put on isatuximab, which in combination with pomalidomide and dexamethasone was approved in Russia in 2020. Expand
Immunotherapy of Multiple Myeloma: Promise and Challenges
TLDR
This review covers the current scope of anti-myeloma immunotherapeutic agents, both those in clinical use and on the horizon, including naked mAbs, ADCs, bi- and multi-targeted m Abs, and CAR T-cells. Expand
Emerging Monoclonal Antibodies for the Treatment of Multiple Myeloma
TLDR
This review focuses on additional monoclonal antibodies currently under clinical study for MM, including several BCMAxCD3-directed bispecifics, the ADCs indatuximab ravtansine and STRO-001, and checkpoint inhibitors, although the future status of the latter is in a state of flux. Expand
Isatuximab for the treatment of relapsed/refractory multiple myeloma
TLDR
Isatuximab is approved in combination with pomalidomide/dexamethasone for the treatment of adults with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomides and a proteasome inhibitor. Expand
Impact of new myeloma agents on the transfusion laboratory.
TLDR
RBC transfusion support for multiple myeloma patients receiving anti-CD38 or anti- CD47 drugs can be optimised by establishing good communication between the clinical teams and TSLs, building electronic notification processes, and ensuring timely completion of baseline pre-transfusion testing and RBC phenotype/genotype prior to starting therapy. Expand
Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma
TLDR
Findings provide preclinical evidence that Ab targeting of CD38 could be an effective therapeutic strategy for the treatment of PEL and clarify the antibody-dependent cell phagocytosis (ADCP). Expand
Isatuximab: A Hopeful Drug for Multiple Myeloma
TLDR
Patients with multiple myeloma may present with bone pain, pathological fracture, anemia, hypercalcemia, renal impairment and recurrent infection. Expand
Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression
TLDR
The alterations observed in symptomatic MM, as compared to its precursor stages and healthy subjects, in the main immune populations, especially the inhibition of effector cells and the activation of immunosuppressive populations are exposed. Expand
Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
TLDR
The crystal structure of CD38 in complex with the Fab fragment of daratumumab is reported, providing its exact epitope on CD38 and the structural insights into the mechanism of action of the antibody drug. Expand
IFN-γ and CD38 in Hyperprogressive Cancer Development
TLDR
It is concluded that IFN-γ may contribute to HP onset through the activation of the inflammasome pathway, immunosuppressive enzyme IDO1 and activation-induced cell death in effector T cells, while the role of CD38 in HP may be associated with theactivation of adenosine receptors, hypoxia pathways and AICD-dependent T-cell depletion. Expand
...
1
2
...

References

SHOWING 1-10 OF 61 REFERENCES
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
TLDR
This pilot study hypothesized that treatment with isatuximab would lead to the induction of novel endogenous tumor-specific antibody and T cell responses and performed immunomonitoring on all four patients who were consecutively enrolled at the University of Utah/Huntsman Cancer Institute. Expand
Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
TLDR
It is proposed that further research on the mechanisms of resistance to anti-CD38 therapy and the development of biomarkers and new backbone regimens with CD38 antibodies will be important steps in building more personalized treatment for patients with MM. Expand
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.
TLDR
The design of a Phase III study (NCT03275285, IKEMA), which is evaluating isatuximab plus carfilzomib and low-dose dexamethasone, versus carfilZomib/dexamethAsone in relapsed/refractory multiple myeloma, and the primary end point is progression-free survival is described. Expand
Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).
TLDR
Isatuximab is an anti-CD38 mAb with potent anti-myeloma effects as monotherapy or together with lenalidomide (Len) + dexamethasone (d) in RRMM. Expand
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
TLDR
Isatuximab demonstrated a manageable safety profile and clinical activity in patients with RRMM and the maximum tolerated dose (MTD) was not reached; no cumulative adverse reactions were noted. Expand
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
TLDR
This study provides a framework to understand response determinants in patients treated with isatuximab based on the number of MoA triggered by CD38 levels of expression, and for the design of effective combinations aimed at capitalizing disrupted tumor–stroma cell protection, augmenting NK lymphocyte–mediated ADCC, or facilitating ADCP in CD38lo MM patients. Expand
A Phase Ib Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone (VCDI) in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplantation
Background: Isatuximab (ISA) is an anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells through direct tumor targeting and immune cell engagement. It has demonstratedExpand
Results from a Phase II Study of Isatuximab As a Single Agent and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
TLDR
The baseline characteristics and demographic data from stage 2 at the selected dosing scheme from stage 1 are reported, and the full efficacy and safety data will be presented at the meeting. Expand
Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM).
TLDR
Isatuximab (ISA) is a humanized anti-CD38 monoclonal antibody with multiple modes of action for killing tumor cells through direct tumor targeting and immune cell engagement. Expand
CD38 antibodies in multiple myeloma: back to the future.
TLDR
Deep responses and prolonged progression-free survival can be achieved in relapsed/refractory MM patients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors, and CD38-targeting antibodies are generally well tolerated and induce partial response or better in heavily pretreated MM patients as monotherapy. Expand
...
1
2
3
4
5
...